1-3 of 3
P C Caron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of Humanized Monoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia

Available to Purchase
S. E. Kossman, D. A. Scheinberg, J. G. Jurcic, J. Jimenez, P. C. Caron
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 2748–2755.
Published: 01 October 1999
View articletitled, A Phase I Trial of Humanized Monoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia
Open the PDF for A Phase I Trial of Humanized Monoclonal Antibody HuM195 (anti-CD33) with Low-Dose Interleukin 2 in Acute Myelogenous Leukemia in another window
Journal Articles

Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

Available to Purchase
P C Caron, L Dumont, D A Scheinberg
Journal: Clinical Cancer Research
Clin Cancer Res (1998) 4 (6): 1421–1428.
Published: 01 June 1998
View articletitled, Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Open the PDF for Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. in another window
Journal Articles

Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.

Available to Purchase
P C Caron, L T Lai, D A Scheinberg
Journal: Clinical Cancer Research
Clin Cancer Res (1995) 1 (1): 63–70.
Published: 01 January 1995
View articletitled, Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Open the PDF for Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. in another window